Buy DOTFM Cas 159277-07-3

Buy DOTFM Cas 159277-07-3

DOTFM, also known as 2,5-dimethoxy-4-trifluoromethylamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM.^[3][1][2][4] It is the α–methylated analogue of 2C-TFM.^[3][2] The drug is the most potent known DOx psychedelic.^[1][2]

According to Daniel Trachsel, DOTFM is active as a psychedelic in humans at doses of 0.3 to 1 mg (300–1,000 μg) orally and its duration is not listed.^[1][2] It is the most potent psychedelic of the DOx family, followed by DOB, which has a dose range of 1 to 3 mg orally.^[1][2]

DOTFM acts as an agonist at the serotonin 5-HT_2A and 5-HT_2C receptors.^[4] In drug discrimination tests in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI.^[4] In addition, (R)-DOTFM robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, with equivalent potency as (R)-DOI.^[5] The drug is around twice as potent as 2C-TFM in animal studies.

In contrast to (R)-DOI, which has extraordinarily potent serotonin 5-HT_2A receptor-mediated anti-inflammatory effects,^[6][7] DOTFM shows no anti-inflammatory effects.^[8] The differences between the drugs in this regard appear to be due to differences in functional selectivity at the serotonin 5-HT_2A receptor.^[8][5]

The chemical synthesis of DOTFM has been described.^[3][4]

DOTFM was first synthesized in 1994 by a team at Purdue University led by David E. Nichols.^[4] The threshold dose in humans was reported by Alexander Shulgin in his 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, who cited personal communication with an anonymous individual in 2003 as the source for the information.^[3][1] Subsequently, Daniel Trachsel described a wider dose range in 2013, although did not report its duration.^[2]

DOTFM is a controlled substance in Canada under phenethylamine blanket-ban language.^[9]